RCE Technologies, Inc. has raised $5.8M over 4 rounds; too few niche peers to rank its valuation yet.
Raised $5.8M across 4 disclosed rounds, last modeled as Recurring offerings.
Valued on the biotech profile — its sector's growth and survival benchmarks differ from the market default, so the same raise is worth more or less here.
Last raise 2.6 yr ago; this sector typically re-raises about every 14 months.
Latest round stepped up 1.8× from the prior — scaling.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
At-risk
Last raise 2.6 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Recurring offering issuermedium confidence
RCE Technologies, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
Issuer structure
Program-like
Frequent filings and follow-ons read more like a securities offering program than discrete startup rounds.
Lifecycle
7.5 yr record
Peak capital year was 2023 with $7.5M across 6 filings.
Market position
ahead of 46% of Biotechnology peers
Capital scale is ahead of 46% of Biotechnology peers; modeled value is above 24% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Lower applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
29 dated financing filings, averaging about 2 months apart.
No clearly named CEO/founder/principal role in the public records surfaced here.
No verified homepage on the profile yet.
Capital program peaked in 2023: $7.5M across 6 filings.
Largest single filing was $2.1M on 2023-11-20.
Filing rows sum to $21.8M, while canonical raised total is $5.8M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
Read this less like a startup funding journey and more like a capital-raising program.
Stage-based valuation and peer labels have lower applicability for this pattern.
The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Canonical filtering should be tightened before using row-level totals for diligence.
Leadership
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Where it sits in Biotechnology
RCE Technologies, Inc. is one of 4291 Biotechnology companies tracked from CARLSBAD. By capital raised it ranks mid-pack (ahead of 46% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
US
Jurisdiction
Rule 506(b)
Reg D exemption
31
Investors (latest)
2023-11-20
First sale
Amount raised vs valuation, by year
This issuer has a dense recurring filing history, so the chart groups filings by year. Solid bars are annual reported capital reported; hatched bars show the latest modeled value est. observed in that year. Use the toggles to overlay data labels and the niche-peer / market average value lines.
Annual capital raised · realLatest value in year · estCumulative funded · real
Dense history compressed: 29 filings shown as 4 yearly buckets. Hover a bucket for filing count, annual capital, and latest modeled value.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Financing ladder & sequence gaps
This looks like a recurring offering series, so a VC stage ladder would be misleading. Showing the filed offering sequence instead.
Initial offering$360K · 2019
Follow-on offering$470K · 2019
Follow-on offering$140K · 2019
Follow-on offering$230K · 2019
Follow-on offering$180K · 2019
Follow-on offering$420K · 2019
Follow-on offering$115K · 2019
Follow-on offering$550K · 2019
Follow-on offering$610K · 2019
Follow-on offering$155K · 2019
Follow-on offering$430K · 2019
Follow-on offering$660K · 2021
Follow-on offering$1.1M · 2021
Follow-on offering$1.3M · 2021
Follow-on offering$410K · 2021
Follow-on offering$1.3M · 2021
Follow-on offering$170K · 2022
Follow-on offering$385K · 2022
Follow-on offering$885K · 2022
Follow-on offering$560K · 2022
Follow-on offering$535K · 2022
Follow-on offering$1.7M · 2022
Follow-on offering$1.6M · 2022
Follow-on offering$500K · 2023
Showing first 24 of 29 filings to keep the sequence readable.
Modeled valuation trajectory
$14.5M
Base estimate est.
$1.5M
Conservative case
$45.6M
Upside case
$10.7M
Modeled post-money
This issuer files recurring offerings, so the model treats stage labels as a loose sizing heuristic, not a clean VC ladder. The estimate anchors on reported filing amounts and dates, then applies benchmark dilution, survival, and markup assumptions. Directional, not a quoted figure.
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
2.6 yr
Elapsed time used
2.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
2 mo
Avg between rounds
$1.2M/yr
Capital velocity
7.5 yr
On record since
2019
First round
29
Rounds on file
How it compares to the market
Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Total raised — vs sector median (real $, all stages)▼ 0.8× of median
This company$5.8M
Sector median$7.2M
Modeled value — vs sector median (estimate, all stages)▼ 0.2× of median
This company$14.5M
Sector median$64.2M
Raised more than 46% of sector peers (real $). Modeled value above 24% of peers (estimate).
Full financing history
This issuer files too frequently for VC stage labels to be meaningful, so rows are shown as initial/follow-on offerings est. instead of Pre-Seed/Seed/Series buckets.
Stage
Amount · real
Announced
Post-money · est
Value · est
Conf.
Initial offering
$360K
2019-01-11
$2.0M
$19.9M
90%
Follow-on offering
$470K
2019-01-11
$2.6M
$25.9M
90%
Follow-on offering
$140K
2019-01-11
$778K
$7.7M
90%
Follow-on offering
$230K
2019-01-11
$1.3M
$12.7M
90%
Follow-on offering
$180K
2019-01-11
$1.0M
$9.9M
90%
Follow-on offering
$420K
2019-01-11
$2.3M
$23.2M
90%
Follow-on offering
$115K
2019-01-11
$639K
$6.3M
90%
Follow-on offering
$550K
2019-01-11
$3.1M
$30.4M
90%
Follow-on offering
$610K
2019-01-11
$3.4M
$33.7M
90%
Follow-on offering
$155K
2019-01-11
$861K
$8.6M
90%
Follow-on offering
$430K
2019-01-11
$2.4M
$23.7M
90%
Follow-on offering
$660K
2021-07-30
$3.7M
$18.6M
90%
Follow-on offering
$1.1M
2021-07-30
$5.5M
$26.7M
90%
Follow-on offering
$1.3M
2021-07-30
$6.5M
$31.6M
90%
Follow-on offering
$410K
2021-07-30
$2.3M
$11.6M
90%
Follow-on offering
$1.3M
2021-07-30
$6.7M
$32.8M
90%
Follow-on offering
$170K
2022-06-22
$944K
$2.8M
90%
Follow-on offering
$385K
2022-06-22
$2.1M
$6.2M
90%
Follow-on offering
$885K
2022-06-22
$4.9M
$14.3M
90%
Follow-on offering
$560K
2022-06-22
$3.1M
$9.1M
90%
Follow-on offering
$535K
2022-06-22
$3.0M
$8.7M
90%
Follow-on offering
$1.7M
2022-06-22
$8.4M
$24.9M
90%
Follow-on offering
$1.6M
2022-06-22
$8.0M
$23.7M
90%
Follow-on offering
$500K
2023-11-20
$2.8M
$3.4M
90%
Follow-on offering
$1.3M
2023-11-20
$6.5M
$8.8M
90%
Follow-on offering
$2.1M
2023-11-20
$10.7M
$14.5M
90%
Follow-on offering
$710K
2023-11-20
$3.9M
$4.8M
90%
Follow-on offering
$1.0M
2023-11-20
$5.0M
$6.8M
90%
Follow-on offering
$1.8M
2023-11-20
$9.1M
$12.4M
90%
What happened at each round
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Initial offering$360K2019-01-11
First recorded raise — entered as Initial offering.
17 investors on this round.
Follow-on offering$470K2019-01-11
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 1.3× larger than the prior — scaling up.
19 investors on this round.
Follow-on offering$140K2019-01-11
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 3.4× smaller than the prior — bridge or down round.
6 investors on this round.
Follow-on offering$230K2019-01-11
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 1.6× larger than the prior — scaling up.
8 investors on this round.
Follow-on offering$180K2019-01-11
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
7 investors on this round.
Follow-on offering$420K2019-01-11
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 2.3× larger than the prior — scaling up.
19 investors on this round.
Follow-on offering$115K2019-01-11
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 3.7× smaller than the prior — bridge or down round.
5 investors on this round.
Follow-on offering$550K2019-01-11
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 4.8× larger than the prior — scaling up.
23 investors on this round.
Follow-on offering$610K2019-01-11
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
23 investors on this round.
Follow-on offering$155K2019-01-11
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 3.9× smaller than the prior — bridge or down round.
6 investors on this round.
Follow-on offering$430K2019-01-11
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 2.8× larger than the prior — scaling up.
20 investors on this round.
Follow-on offering$660K2021-07-30
Raised again after 31 mo — slower than the ~14 mo sector norm.
Round 1.5× larger than the prior — scaling up.
8 investors on this round.
Follow-on offering$1.1M2021-07-30
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 1.7× larger than the prior — scaling up.
10 investors on this round.
Follow-on offering$1.3M2021-07-30
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
13 investors on this round.
Follow-on offering$410K2021-07-30
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 3.2× smaller than the prior — bridge or down round.
4 investors on this round.
Follow-on offering$1.3M2021-07-30
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 3.3× larger than the prior — scaling up.
14 investors on this round.
Follow-on offering$170K2022-06-22
Raised 11 mo later, in step with the ~14 mo sector norm.
Round 7.9× smaller than the prior — bridge or down round.
6 investors on this round.
Follow-on offering$385K2022-06-22
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 2.3× larger than the prior — scaling up.
12 investors on this round.
Follow-on offering$885K2022-06-22
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 2.3× larger than the prior — scaling up.
25 investors on this round.
Follow-on offering$560K2022-06-22
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 1.6× smaller than the prior — bridge or down round.
19 investors on this round.
Follow-on offering$535K2022-06-22
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
17 investors on this round.
Follow-on offering$1.7M2022-06-22
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 3.1× larger than the prior — scaling up.
43 investors on this round.
Follow-on offering$1.6M2022-06-22
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
39 investors on this round.
Follow-on offering$500K2023-11-20
Raised 17 mo later, in step with the ~14 mo sector norm.
Round 3.2× smaller than the prior — bridge or down round.
6 investors on this round.
Follow-on offering$1.3M2023-11-20
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 2.6× larger than the prior — scaling up.
25 investors on this round.
Follow-on offering$2.1M2023-11-20
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 1.6× larger than the prior — scaling up.
37 investors on this round.
Follow-on offering$710K2023-11-20
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 3.0× smaller than the prior — bridge or down round.
12 investors on this round.
Follow-on offering$1.0M2023-11-20
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 1.4× larger than the prior — scaling up.
18 investors on this round.
Follow-on offering$1.8M2023-11-20
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 1.8× larger than the prior — scaling up.
31 investors on this round.
Intelligence
2024 ~Q1
Modeled next raise · ~2mo cadence
$3.3M
Modeled next size est.range $2.2M–$5.3M
1.8×
Last step-up
$1.2M/yr
Capital velocity
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Key people & operators
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
RCE Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
United States
Country of record
US
Jurisdiction
1791860
SEC CIK
Similar companies
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
How much funding has RCE Technologies, Inc. raised?
RCE Technologies, Inc. has raised approximately $5.8M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is RCE Technologies, Inc.'s estimated valuation?
Provath's modeled valuation for RCE Technologies, Inc. is approximately $14.5M (modeled range $1.5M–$45.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is RCE Technologies, Inc. at?
RCE Technologies, Inc. shows a recurring offering pattern rather than a clean VC stage progression. Its most recent recorded round closed around Mon Nov 20.
What does RCE Technologies, Inc. do and where is it based?
RCE Technologies, Inc. operates in the Biotechnology sector, based in CARLSBAD.
Explore related
See where RCE Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at RCE Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.